Christopher M Jones1, Danielle J Byrd2, Thomas J Clarke3, Tony B Campbell2, Chideha Ohuoha4, Elinore F McCance-Katz5. 1. Office of Strategy and Innovation, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, 4700 Buford Highway NE, Atlanta, GA, 30341, USA. Electronic address: fjr0@cdc.gov. 2. Division of Pharmacologic Therapies, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, MD, 20852, USA. 3. National Mental Health and Substance Use Policy Laboratory, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, MD, 20852, USA. 4. Office of the Director, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, MD, 20852, USA. 5. Office of the Assistant Secretary for Mental Health and Substance Use, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, MD, 20852, USA.
Abstract
BACKGROUND: Given rising rates of opioid use disorder (OUD) and related consequences, opioid treatment programs (OTPs) can play a pivotal role in the U.S. opioid crisis. There is a paucity of recent research to guide how best to leverage OTPs in the opioid response. METHODS: We conducted a national survey of U.S. OTPs using a 46-question electronic survey instrument covering three domains: 1) OTP characteristics; 2) services offered; and 3) current clinical practices. Descriptive statistics and multivariable logistic regression examined variables in these domains. RESULTS: Among responding OTPs, 32.4% reported using all three medications for OUD treatment; 95.8% used methadone, 61.8% used buprenorphine, and 43.9% used naltrexone. The mean (SD) number of patients currently receiving methadone was 383 (20.4), buprenorphine 51 (7.0), extended-release naltrexone 6 (1.0). Viral hepatitis testing was provided by 60.9% of OTPs, 15.3% provided hepatitis B vaccination, 14.9% provided hepatitis A vaccination, and 12.6% provided medication treatment for hepatitis C virus infection. HIV testing was provided by 60.7% of OTPs, 9.5% provided pre-exposure prophylaxis, and 8.4% provided medication treatment for HIV. OTP characteristics associated with using all three forms of medications for OUD included: providing medication for alcohol use disorder (aOR = 5.24, 95% CI:2.99-9.16), providing telemedicine services (aOR = 3.82, 95% CI:2.14-6.84), and directly providing naloxone to patients (aOR = 2.57, 95% CI:1.53-4.29). Multiple barriers to providing buprenorphine and extended-release naltrexone were identified. CONCLUSIONS: Efforts are needed to increase availability of all medications approved to treat OUD in OTPs, integrate infectious disease-related services, and expand the reach of OTPs in the U.S. Published by Elsevier B.V.
BACKGROUND: Given rising rates of opioid use disorder (OUD) and related consequences, opioid treatment programs (OTPs) can play a pivotal role in the U.S. opioid crisis. There is a paucity of recent research to guide how best to leverage OTPs in the opioid response. METHODS: We conducted a national survey of U.S. OTPs using a 46-question electronic survey instrument covering three domains: 1) OTP characteristics; 2) services offered; and 3) current clinical practices. Descriptive statistics and multivariable logistic regression examined variables in these domains. RESULTS: Among responding OTPs, 32.4% reported using all three medications for OUD treatment; 95.8% used methadone, 61.8% used buprenorphine, and 43.9% used naltrexone. The mean (SD) number of patients currently receiving methadone was 383 (20.4), buprenorphine 51 (7.0), extended-release naltrexone 6 (1.0). Viral hepatitis testing was provided by 60.9% of OTPs, 15.3% provided hepatitis B vaccination, 14.9% provided hepatitis A vaccination, and 12.6% provided medication treatment for hepatitis C virus infection. HIV testing was provided by 60.7% of OTPs, 9.5% provided pre-exposure prophylaxis, and 8.4% provided medication treatment for HIV. OTP characteristics associated with using all three forms of medications for OUD included: providing medication for alcohol use disorder (aOR = 5.24, 95% CI:2.99-9.16), providing telemedicine services (aOR = 3.82, 95% CI:2.14-6.84), and directly providing naloxone to patients (aOR = 2.57, 95% CI:1.53-4.29). Multiple barriers to providing buprenorphine and extended-release naltrexone were identified. CONCLUSIONS: Efforts are needed to increase availability of all medications approved to treat OUD in OTPs, integrate infectious disease-related services, and expand the reach of OTPs in the U.S. Published by Elsevier B.V.
Authors: Pooja Lagisetty; Claire Garpestad; Angela Larkin; Colin Macleod; Derek Antoku; Stephanie Slat; Jennifer Thomas; Victoria Powell; Amy S B Bohnert; Lewei A Lin Journal: Drug Alcohol Depend Date: 2021-02-13 Impact factor: 4.492
Authors: Katie B Biello; Matthew J Mimiaga; Pablo K Valente; Nimish Saxena; Angela R Bazzi Journal: Curr HIV/AIDS Rep Date: 2021-04-27 Impact factor: 5.495
Authors: Kathy Le; Tzuan A Chen; Isabel Martinez Leal; Virmarie Correa-Fernández; Ezemenari M Obasi; Bryce Kyburz; Teresa Williams; Kathleen Casey; Matthew Taing; Daniel P O'Connor; Lorraine R Reitzel Journal: Int J Environ Res Public Health Date: 2021-10-06 Impact factor: 3.390